The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam
- PMID: 3931107
- DOI: 10.1055/s-2007-1017385
The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam
Abstract
A double-blind study was performed in 83 patients with generalized anxiety disorder comparing daily doses of 5 and 10 mg ritanserin (a selective antagonist of serotonine S2 receptors) versus placebo and 4 mg lorazepam as reference drug. Patients treated with 10 mg ritanserin or 4 mg lorazepam improved significantly better (p less than 0.05) after two weeks than those treated with placebo. On the other hand a daily dose of 5 mg ritanserin appeared to be not superior to placebo. Patients treated with 4 mg lorazepam complained significantly more about sedation and dizziness than patients treated with 10 mg ritanserin (p less than 0.05).
Similar articles
-
Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.Int J Clin Pharmacol Res. 1987;7(2):111-9. Int J Clin Pharmacol Res. 1987. PMID: 3108171 Clinical Trial.
-
[Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].Encephale. 1997 Jul-Aug;23(4):290-9. Encephale. 1997. PMID: 9417395 Clinical Trial. French.
-
A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.J Clin Psychopharmacol. 1993 Dec;13(6):429-37. J Clin Psychopharmacol. 1993. PMID: 7907097 Clinical Trial.
-
Studies with alpidem in normal volunteers and anxious patients.Pharmacopsychiatry. 1990 May;23 Suppl 3:120-3. doi: 10.1055/s-2007-1014547. Pharmacopsychiatry. 1990. PMID: 1974071 Review.
-
Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.J Clin Psychiatry. 1990 Sep;51 Suppl:31-9. J Clin Psychiatry. 1990. PMID: 2211564 Review.
Cited by
-
Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.Psychopharmacology (Berl). 1987;92(1):14-24. doi: 10.1007/BF00215473. Psychopharmacology (Berl). 1987. PMID: 3110824
-
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.Br J Pharmacol. 1994 Mar;111(3):797-802. doi: 10.1111/j.1476-5381.1994.tb14808.x. Br J Pharmacol. 1994. PMID: 7912626 Free PMC article.
-
Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety.Psychopharmacology (Berl). 1994 Feb;114(1):90-6. doi: 10.1007/BF02245448. Psychopharmacology (Berl). 1994. PMID: 7846211
-
Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist.Biol Psychiatry. 2007 Nov 15;62(10):1111-8. doi: 10.1016/j.biopsych.2006.11.023. Epub 2007 May 23. Biol Psychiatry. 2007. PMID: 17524369 Free PMC article.
-
The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.Br J Pharmacol. 1993 Nov;110(3):1079-84. doi: 10.1111/j.1476-5381.1993.tb13924.x. Br J Pharmacol. 1993. PMID: 7507776 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical